BCDA NASDAQ
Credit Risk of going bust: lower than 62% of companies Debt: 2.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down 99.7%), BioCardia, Inc. would be worth roughly what it owes.
Total debt $293K against a stock market value of $14.0M.
Distance to default 6.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $146K (short-term plus half of long-term), stock volatility 68.0%; Altman Z'' -123.97. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Sunnyvale, CA 94085
US
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Altman Peter | P-Purchase | 300 | $0.95 | 2026-10-16 |
| Altman Peter | P-Purchase | 200 | $0.95 | 2026-10-15 |
| Altman Peter | P-Purchase | 1,000 | $1.03 | 2026-09-29 |
| Altman Peter | P-Purchase | 1,900 | $1.05 | 2026-09-23 |
| Altman Peter | P-Purchase | 800 | $1.09 | 2026-09-03 |